Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 26 von 304

Details

Autor(en) / Beteiligte
Titel
Trial of Deferiprone in Parkinson’s Disease
Ist Teil von
  • The New England journal of medicine, 2022-12, Vol.387 (22), p.2045-2055
Ort / Verlag
United States: Massachusetts Medical Society
Erscheinungsjahr
2022
Quelle
Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
Beschreibungen/Notizen
  • Iron deposition in the substantia nigra has been implicated in Parkinson’s disease. Chelation with deferiprone reduced brain iron content but led to worse scores on scales of the movement disorder at 36 weeks.
Sprache
Englisch
Identifikatoren
ISSN: 0028-4793, 1533-4406
eISSN: 1533-4406
DOI: 10.1056/NEJMoa2209254
Titel-ID: cdi_swepub_primary_oai_DiVA_org_uu_491089
Format
Schlagworte
Administration, Oral, Aging, Aging General, Antiparkinson Agents - administration & dosage, Antiparkinson Agents - adverse effects, Antiparkinson Agents - pharmacology, Antiparkinson Agents - therapeutic use, Basal ganglia, Body weight, Brain - diagnostic imaging, Brain Chemistry, Central nervous system diseases, Clinical trials, Cognitive ability, Deferiprone - administration & dosage, Deferiprone - adverse effects, Deferiprone - pharmacology, Deferiprone - therapeutic use, Disease Progression, Dopamine, Dopamine Agents - administration & dosage, Dopamine Agents - adverse effects, Dopamine Agents - pharmacology, Dopamine Agents - therapeutic use, Dopamine receptors, Double-Blind Method, Double-blind studies, Genetics, Geriatrics, Hematology, Humans, Iron, Iron - analysis, Iron - metabolism, Iron Chelating Agents - administration & dosage, Iron Chelating Agents - adverse effects, Iron Chelating Agents - pharmacology, Iron Chelating Agents - therapeutic use, Levodopa, Levodopa - therapeutic use, Life Sciences, Magnetic resonance imaging, Metabolism, Movement disorders, Neurodegenerative diseases, Neuroimaging, Neurology, Neuroscience, Neurosurgery, Neutropenia, Neutropenia - chemically induced, Oncology, Oncology General, Parkinson Disease, Parkinson Disease - drug therapy, Parkinson Disease - metabolism, Parkinson Disease - physiopathology, Parkinson's disease, Placebos, Quality of life, Substantia nigra, Substantia Nigra - chemistry, Substantia Nigra - diagnostic imaging, Substantia Nigra - drug effects, Substantia Nigra - metabolism

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX